Friday, March 10, 2006

Epigenomics confirms lead marker for prediction of breast cancer relapse

Epigenomics, March 9, 2006
a molecular diagnostics company developing tests based on DNA methylation today announced positive results of a study investigating the prognostic power of its proprietary prognostic PITX2 DNA methylation biomarker in early stage breast cancer. In addition, the study validated one other prognostic biomarker.The study again confirmed that the marker is of prognostic value for making treatment decisions in cancer. Previously, Epigenomics has demonstrated a correlation between the presence of low levels of PITX2 gene methylation and low risk of metastasis development and vice versa in prostate cancer patients and in patients with node-negative, hormone-receptor positive breast cancer, a less aggressive form of the cancer. The present study investigated 395 breast cancer patients suffering from lymph node positive cancers, a more aggressive form. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */